Renalytix Deferred Long Term Liab vs Net Working Capital Analysis
RNLX Stock | USD 0.44 0.08 15.38% |
Renalytix financial indicator trend analysis is much more than just breaking down Renalytix AI prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Renalytix AI is a good investment. Please check the relationship between Renalytix Deferred Long Term Liab and its Net Working Capital accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renalytix AI. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Deferred Long Term Liab vs Net Working Capital
Deferred Long Term Liab vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Renalytix AI Deferred Long Term Liab account and Net Working Capital. At this time, the significance of the direction appears to have strong relationship.
The correlation between Renalytix's Deferred Long Term Liab and Net Working Capital is 0.68. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Renalytix AI, assuming nothing else is changed. The correlation between historical values of Renalytix's Deferred Long Term Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Renalytix AI are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Deferred Long Term Liab i.e., Renalytix's Deferred Long Term Liab and Net Working Capital go up and down completely randomly.
Correlation Coefficient | 0.68 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Net Working Capital
Most indicators from Renalytix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Renalytix AI current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renalytix AI. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Renalytix's Tax Provision is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 52 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 6.03 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 58.3M | 43.1M | 49.5M | 33.5M | Cost Of Revenue | 2.1M | 2.7M | 3.1M | 3.3M |
Renalytix fundamental ratios Correlations
Click cells to compare fundamentals
Renalytix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Renalytix fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 41.3M | 102.6M | 63.3M | 42.1M | 48.4M | 51.0M | |
Total Current Liabilities | 3.4M | 7.3M | 12.2M | 16.1M | 18.6M | 19.5M | |
Total Stockholder Equity | 36.0M | 95.1M | 43.2M | 18.5M | 21.2M | 40.5M | |
Net Tangible Assets | 18.8M | 71.5M | 30.6M | 7.0M | 8.0M | 7.6M | |
Net Debt | (12.7M) | (64.8M) | (28.6M) | (12.5M) | (11.3M) | (11.8M) | |
Retained Earnings | 34.9M | 3.8M | (53.0M) | (99.2M) | (89.3M) | (84.8M) | |
Cash | 13.3M | 65.2M | 41.3M | 24.7M | 28.4M | 28.2M | |
Non Current Assets Total | 22.4M | 26.6M | 15.8M | 13.8M | 15.9M | 18.0M | |
Cash And Short Term Investments | 14.3M | 74.5M | 44.1M | 26.1M | 30.1M | 30.9M | |
Net Receivables | 18K | 1.2M | 901K | 776K | 892.4K | 536.5K | |
Common Stock Shares Outstanding | 29.5M | 35.7M | 36.4M | 41.1M | 37.0M | 29.1M | |
Liabilities And Stockholders Equity | 41.3M | 102.6M | 63.3M | 42.1M | 48.4M | 51.0M | |
Non Current Liabilities Total | 2.0M | 213K | 7.9M | 7.5M | 8.7M | 9.1M | |
Other Stockholder Equity | 2.8M | 82.8M | 95.9M | 118.8M | 136.6M | 143.4M | |
Total Liab | 5.3M | 7.5M | 20.1M | 23.7M | 27.2M | 28.6M | |
Net Invested Capital | 36.2M | 71.5M | 42.9M | 30.4M | 35.0M | 38.4M | |
Short Long Term Debt | 121K | 53K | 4.7M | 4.5M | 5.1M | 5.4M | |
Total Current Assets | 18.9M | 76.0M | 47.4M | 28.3M | 32.6M | 33.0M | |
Net Working Capital | 15.5M | 59.7M | 33.0M | 12.2M | 14.0M | 23.7M | |
Common Stock | 192K | 233K | 241K | 299K | 343.9K | 221.8K | |
Other Current Liab | 271K | 5.2M | 4.9M | 10K | 11.5K | 10.9K | |
Property Plant And Equipment Net | 945K | 2.5M | 3.1M | 1.2M | 1.4M | 1.8M | |
Accounts Payable | 2.9M | 1.8M | 2.5M | 11.5M | 13.2M | 13.9M | |
Non Currrent Assets Other | 83K | (1.1M) | 1.5M | 51K | 58.7K | 49.7K | |
Other Assets | 2.4M | 7.2M | 1.2M | 1.1M | 1.3M | 1.2M | |
Short Term Investments | 982K | 9.3M | 2.7M | 1.5M | 1.7M | 1.6M | |
Inventory | 326K | 353K | 1.2M | 718K | 825.7K | 562.5K | |
Other Current Assets | 4.3M | (1K) | 2.2M | 566K | 509.4K | 483.9K | |
Property Plant And Equipment Gross | 945K | 2.7M | 3.6M | 1.2M | 1.4M | 1.9M | |
Accumulated Other Comprehensive Income | (1.9M) | 8.3M | (915K) | (1.5M) | (1.3M) | (1.2M) | |
Capital Stock | 192K | 233K | 228K | 299K | 343.9K | 247.9K | |
Property Plant Equipment | 945K | 2.5M | 2.6M | 1.2M | 1.4M | 1.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Renalytix AI offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Renalytix's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Renalytix Ai Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Renalytix Ai Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renalytix AI. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Renalytix Stock analysis
When running Renalytix's price analysis, check to measure Renalytix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renalytix is operating at the current time. Most of Renalytix's value examination focuses on studying past and present price action to predict the probability of Renalytix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Renalytix's price. Additionally, you may evaluate how the addition of Renalytix to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Renalytix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renalytix. If investors know Renalytix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renalytix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.76) | Revenue Per Share 0.052 | Quarterly Revenue Growth (0.41) | Return On Assets (0.88) | Return On Equity (6.51) |
The market value of Renalytix AI is measured differently than its book value, which is the value of Renalytix that is recorded on the company's balance sheet. Investors also form their own opinion of Renalytix's value that differs from its market value or its book value, called intrinsic value, which is Renalytix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renalytix's market value can be influenced by many factors that don't directly affect Renalytix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Renalytix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Renalytix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renalytix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.